Liquidia Corporation (LQDA)Healthcare | Drug Manufacturers - Specialty & Generic | Morrisville, United States | NasdaqCM
67.69 USD
-2.25
(-3.217%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 68.25 +0.56 (0.827%) ⇧ (Aug. 28, 2026, 7:49 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 3:22 a.m. EDT
Liquidia presents a compelling dichotomy: a fundamentally superior business currently trading at a discount due to recent price weakness, yet facing short-term speculative headwinds. The core investment thesis is robust; the company boasts exceptional profitability with a 30% profit margin and 1.32 ROE, alongside explosive 18% revenue growth and a massive 179% surge in annual returns over the last fiscal year. The forward P/E of 12x suggests the market has priced in a severe slowdown that the current fundamentals do not support. However, the short-term outlook is clouded by aggressive selling pressure. Insider sales totaling over $12 million recently, combined with a sharp 20% drop in the last two weeks, have triggered a defensive response from options traders. The heavy put volume at lower strikes indicates fear of a deeper retracement, while the statistical forecast model offers only a weak lean upward. This tension creates a 'buy the dip' opportunity for long-term holders, but the immediate path is likely choppy as the market digests the insider activity and validates the recent decline. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.178165 |
| AutoARIMA | 0.331925 |
| AutoETS | 0.334581 |
| MSTL | 0.369438 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 28% |
| H-stat | 25.57 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.036 |
| Excess Kurtosis | -0.55 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 93.738 |
| Revenue per Share | 5.148 |
| Market Cap | 6,058,856,960 |
| Trailing P/E | 48.35 |
| Forward P/E | 11.98 |
| Beta | 0.57 |
| Profit Margins | 30.74% |
| Previous Name | Liquidia Technologies, Inc. |
| Website | https://www.liquidia.com |
As of Aug. 22, 2026, 3:22 a.m. EDT: Speculators are positioning for significant volatility with heavy put volume at lower strikes ($45-$60) suggesting a floor defense, while call interest clusters around the $90 resistance level. The $100 strike shows notable volume spikes in both directions, indicating a key battleground for the next leg. Implied volatility remains elevated across the board, reflecting uncertainty about whether the recent rally can sustain or if a correction toward the $40-$50 range is imminent.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.447166 |
| Address1 | 419 Davis Drive |
| Address2 | Suite 100 |
| All Time High | 93.61 |
| All Time Low | 2.25 |
| Ask | 87.32 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.6 - Buy |
| Average Daily Volume10 Day | 1,354,100 |
| Average Daily Volume3 Month | 1,920,903 |
| Average Volume | 1,920,903 |
| Average Volume10Days | 1,354,100 |
| Beta | 0.572 |
| Bid | 50.4 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 2.19 |
| City | Morrisville |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 67.69 |
| Current Ratio | 2.312 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 70.305 |
| Day Low | 67.57 |
| Debt To Equity | 93.738 |
| Display Name | Liquidia |
| Earnings Call Timestamp End | 1,786,537,800 |
| Earnings Call Timestamp Start | 1,786,537,800 |
| Earnings Timestamp | 1,786,537,800 |
| Earnings Timestamp End | 1,793,709,000 |
| Earnings Timestamp Start | 1,793,709,000 |
| Ebitda | 169,768,000 |
| Ebitda Margins | 0.3765 |
| Enterprise To Ebitda | 36.279 |
| Enterprise To Revenue | 13.659 |
| Enterprise Value | 6,158,966,784 |
| Eps Current Year | 3.22 |
| Eps Forward | 5.65 |
| Eps Trailing Twelve Months | 1.4 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 919 328 4402 |
| Fifty Day Average | 79.133 |
| Fifty Day Average Change | -11.443001 |
| Fifty Day Average Change Percent | -0.14460465 |
| Fifty Two Week Change Percent | 144.7166 |
| Fifty Two Week High | 93.61 |
| Fifty Two Week High Change | -25.919998 |
| Fifty Two Week High Change Percent | -0.27689347 |
| Fifty Two Week Low | 21.15 |
| Fifty Two Week Low Change | 46.54 |
| Fifty Two Week Low Change Percent | 2.2004728 |
| Fifty Two Week Range | 21.15 - 93.61 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,532,611,800,000 |
| Float Shares | 63,315,904 |
| Forward Eps | 5.65 |
| Forward P E | 11.980531 |
| Free Cashflow | 74,296,128 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 216 |
| Fullday Change | -2.25 |
| Fullday Change Percent | -3.21704 |
| Fullday Price | 68.25 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.92542 |
| Gross Profits | 417,276,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.11319 |
| Held Percent Institutions | 0.81957 |
| Implied Shares Outstanding | 89,508,891 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina. |
| Long Name | Liquidia Corporation |
| Market | us_market |
| Market Cap | 6,058,856,960 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_22761611 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-08-28 |
| Net Income To Common | 138,606,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 6,254,881,303 |
| Number Of Analyst Opinions | 8 |
| Open | 69.99 |
| Operating Cashflow | 167,708,000 |
| Operating Margins | 0.49812 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 919 328 4400 |
| Post Market Change | 0.55999756 |
| Post Market Change Percent | 0.8272973 |
| Post Market Price | 68.25 |
| Post Market Time | 1,787,960,941 |
| Prev Name | Liquidia Technologies, Inc. |
| Previous Close | 69.94 |
| Price Eps Current Year | 21.02174 |
| Price Hint | 2 |
| Price To Book | 30.908676 |
| Price To Sales Trailing12 Months | 13.437043 |
| Profit Margins | 0.30739 |
| Quick Ratio | 2.075 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.625 |
| Region | US |
| Regular Market Change | -2.25 |
| Regular Market Change Percent | -3.21704 |
| Regular Market Day High | 70.305 |
| Regular Market Day Low | 67.57 |
| Regular Market Day Range | 67.57 - 70.305 |
| Regular Market Open | 69.99 |
| Regular Market Previous Close | 69.94 |
| Regular Market Price | 67.69 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 925,267 |
| Return On Assets | 0.27039 |
| Return On Equity | 1.3181599 |
| Revenue Growth | 18.427 |
| Revenue Per Share | 5.148 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 89,508,891 |
| Shares Percent Shares Out | 0.1325 |
| Shares Short | 11,856,100 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 12,333,107 |
| Short Name | Liquidia Corporation |
| Short Percent Of Float | 0.16430001 |
| Short Ratio | 7.42 |
| Source Interval | 15 |
| State | NC |
| Symbol | LQDA |
| Target High Price | 130.0 |
| Target Low Price | 90.0 |
| Target Mean Price | 107.75 |
| Target Median Price | 109.0 |
| Total Cash | 284,180,992 |
| Total Cash Per Share | 3.175 |
| Total Debt | 182,896,000 |
| Total Revenue | 450,907,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 1.4 |
| Trailing P E | 48.350002 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 50.14075 |
| Two Hundred Day Average Change | 17.549252 |
| Two Hundred Day Average Change Percent | 0.3499998 |
| Type Disp | Equity |
| Volume | 925,267 |
| Website | https://www.liquidia.com |
| Zip | 27,560 |